Ventyx Biosciences
San Diego, US · Founded 2019 · Delaware corporation · 229 employees on LinkedIn · 5 known investors
Founders & leadership
MS
Mark S. FormanExecutive
MM
Matthew MooreExecutive
JN
John NussExecutive
JC
Jigar ChokseyNamed on SEC filing
MA
Martin AusterNamed on SEC filing
CW
Christopher W. KruegerNamed on SEC filing
Board
SS
Somasundaram SubramaniamBoard director
RM
AR
RG
SG
Sheila GujrathiBoard director
WW
William WhiteBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$192.3M disclosed across 3 rounds · 2021–2024
▶$27MraisedSep 2024 · 1 investors · OtherRule 506(b)
▶$27MraisedSep 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Sheila GujrathiDirector
- Mark S. FormanExecutive Officer
- William WhiteDirector
- Allison HulmeDirector
- Matthew MooreExecutive Officer
- Onaiza Cadoret-ManierDirector
- Somasundaram SubramaniamDirector
- Raju MohanExecutive Officer, Director
- John NussExecutive Officer
- Offering amount
- $27M
- Amount sold
- $27M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51MraisedSep 2021 · 17 investors · OtherRule 506(b)
▶$51MraisedSep 2021 · 17 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Christopher W. KruegerExecutive Officer
- William WhiteDirector
- Jigar ChokseyDirector
- Richard GasterDirector
- Raju MohanExecutive Officer, Director
- Sheila GujrathiDirector
- Somasundaram SubramaniamDirector
- Aaron RoystonDirector
- Martin AusterExecutive Officer
- Offering amount
- $51M
- Amount sold
- $51M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$114.3MraisedJul 2021 · 24 investors · OtherRule 506(b)
▶$114.3MraisedJul 2021 · 24 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raju MohanExecutive Officer, Director
- Jigar ChokseyDirector
- Sheila GujrathiDirector
- Aaron RoystonDirector
- Somasundaram SubramaniamDirector
- Martin AusterExecutive Officer
- William WhiteDirector
- Christopher W. KruegerExecutive Officer
- Richard GasterDirector
- Offering amount
- $114.3M
- Amount sold
- $114.3M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Exelixis5 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Guardant Health4 shared keywordsGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Vendelux4 shared keywordsVendelux runs an AI-based event intelligence platform that helps B2B teams pick events, book meetings and attribute pipeline.
Scholar Rock3 shared keywordsScholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases. The company uses a selective protein targeting approach designed to inhibit disease mechanisms rather than manage their downstream effects.
Alumis3 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Relay3 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Clementia3 shared keywordsIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
TipRanks3 shared keywordsFinancial analysis and stock research platform.
Companies competing with Ventyx Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Ventyx Biosciences's investors?
- Ventyx Biosciences's investors include New Science Ventures, Third Point Ventures, venBio Partners, SilverArc Private, venBio Global Strategic.
- How much funding has Ventyx Biosciences raised?
- Ventyx Biosciences has disclosed $192.3M raised across 3 rounds.
- Where is Ventyx Biosciences headquartered?
- Ventyx Biosciences is headquartered in San Diego, US.